Abstract
Background
Environmental factors may explain observations of temporal variations in type 1 diabetes incidence [Gamble, 1975; Hermann et al., 2003; Stefan et al., 2014] . HLA-DQ2 and -DQ8 risk haplotypes [Kockum et al., 1999; EURODIAB, 2000; Kukko et al., 2004] and also non-HLA genetic factors are likely to contribute to the high incidence in countries like Sweden [Graham et al., 2002; Smyth et al., 2006; Concannon et al., 2009] . The possible influence of viral infections as a trigger of islet autoimmunity, clinical onset of type 1 diabetes, or both has been reviewed [Graves et al., 1997; Kolehmainen et al., 2013] . Several studies have suggested that enterovirus may be associated with the appearance of islet autoimmunity, type 1 diabetes, or both [Lonnrot et al., 2000; Serreze et al., 2000; Cabrera-Rode et al., 2003] .
Ljungan virus (LV), a Parechovirus possibly pathogenic to humans Ekstrom et al., 2007] has been suggested to contribute to type 1 diabetes Niklasson et al., 2003a] . LV was defined as a separate species in the Parechovirus genus Niklasson et al., 2003b] . Formerly classified as an Enterovirus the Parechovirus was later reclassified as a separate genus in the Picornaviridae family containing Human Parechoviruses (HPeV) and Ljungan virus. Type 1 and 2 HPeV, formerly known as Echovirus 22 and 23, respectively, have been associated with type 1 diabetes [Niklasson et al., 1998; Johansson et al., 2002] .
LV was first isolated in a bank vole, Myodes glareolus, from the valley of the river Ljungan in northern Sweden [Niklasson et al., 2003b] . Bank voles captured in the wild developed diabetes and had not only antibodies against LV but also autoantibodies against glutamic acid decarboxylase, islet antigen-2 and insulin [Niklasson et al., 2003a] . The population of bank voles in northern Sweden fluctuates with multiannual population cycles showing similarities with the fluctuations of the incidence of type 1 diabetes [Niklasson et al., 2003b; Hornfeldt et 5 al., 2005] . Levels of LV antibodies were increased in young age-at-onset of type 1 diabetes children but a possible relationship to the incidence of type 1 diabetes could either not be determined [Niklasson et al., 2006] or was suggestive [Niklasson et al., 2003a ]. In previous investigations high level LV antibodies were found to fluctuate with season and to correlate with type 1 diabetes indicating that past exposure to LV may be associated with type 1 diabetes [Nilsson et al., 2009; Nilsson et al., 2013] .
The specificity of the LV antibody analysis was questioned as children are often infected by any of 16 known strains of HPeV and it could not be excluded that LV antibodies would be explained by reactivity with other viruses.
The aim of this study was to compare IgM-and IgG-antibodies to both LV and HPeV peptides detected in an exploratory indirect antibody capture immunoassay [Blomberg et al., 2012] with LV antibodies detected in a RBA [Niklasson et al., 2003a; Nilsson et al., 2009; Nilsson et al., 2013] and to test whether these LV antibodies were related to islet autoantibodies or to type 1 diabetes-associated HLA-DQ genotypes. The exploratory suspension multiplex immunoassay analyses were performed on samples from 69 of the type 1 diabetes children and 294 of the controls.
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Materials and Methods
Serum
All samples were obtained after informed consent from patients and parents and the study was approved by the Research Ethics Committee, University of Umeå, Umeå, Sweden.
There are no financial or other conflicts of interest for any of the authors.
Ljungan virus antibody RBA
Coupled in vitro transcription translation of the Ljungan virus isolate 87-012 representing 812 amino acids (6-817) of the LV-1 protein in a pCRII-TOPO vector [Nilsson et al., 2009; Nilsson et al., 2013] was performed in a reaction mixture containing 2 µg of pCRII-TOPO vector, 50 µl TNT®rabbit reticulocyte lysate, 4 µl TNT®reaction buffer, 2 µl amino acid mixture without methionine, 2 µl RNasin® Ribonuclease inhibitor, 2 µl SP6 RNA Polymerase, (all from Promega Corporation, Madison, WI, USA), 4 µl 35S-methionine (N1000 Ci/mmol, Amersham, Buckinghamshire, UK) and nuclease-free water to a final volume of 100 µl. The reaction mixture was incubated for 90 min at 30 °C with shaking (300 rpm in an Eppendorf Thermomixer, Eppendorf, Hamburg, Germany). The translation product 7 was immediately subjected to gel filtration on Illustra™ NAP-5 Columns (GE Healthcare Bio-Sciences, Uppsala, Sweden) and radioactivity incorporated into protein was determined runs into in-house units (U) using individual standard curves generated by six step doubling dilutions of high-titer guinea pig antisera (Antiserum 174 F #4) [Niklasson et al., 2003a] [ Niklasson et al., 2003b] . Intra-assay CV for duplicate determinations was 4% and the interassay CV was 10%. The cut off for antibodies to this LV-1-polyprotein (LV-1A) was set to 56 U/ml, which corresponded to the 75 th percentile of results of the controls´ LV-1A.
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Suspension multiplex immunoassay.
Synthetic peptides representing HPeV, LV, Aichi virus and poliovirus (Table I) were used for detecting IgM and IgG antibodies in an exploratory suspension immunoassay [Blomberg et al., 2012] . The Aichi virus species in the Kobuvirus genus and the Poliovirus subtype of the Enterovirus C species from the Enterovirus genus both belong to the Picornaviridae family.
The synthetic peptides were selected from a larger set of peptides containing predicted epitopes [Kolaskar and Tongaonkar, 1990; Larsen et al., 2006] in the Immune Epitope Database (IEDB, http://tools.immuneepitope.org ). Frequent and strongly reactive peptides in 70 blood donor sera were chosen. All peptides were 30-mers and had a triethylene glycol spacer coupled at the NH 2 -terminal end [Elfaitouri et al., 2013] . Coupling of proteins and peptides to carboxylated microspheres was performed as described [Blomberg et al., 2012] .
Haemophilus influenzae type B vaccine, bovine fetuin for fetuin-IgM and dialyzed inactivated
Polio Vaccine (IPV, Imovax® Polio; Sanofi Pasteur MSD, Lyon, France) were used as positive controls and coupled according to the protocol above [Blomberg et al., 2012] .
Unprocessed ("naked") Luminex beads without any bound antigen, were used to control for nonspecific binding as described previously [Elfaitouri et al., 2013] . The exploratory suspension multiplex immunoassay for IgG and IgM required only 5-10 µl of serum or plasma. IgG was detected using biotinylated protein G [Bjorck and Blomberg, 1987] and IgM using biotinylated anti-human IgM (affinity purified µ-chain specific, Sigma-Aldrich, S:t Louis, MO, USA) as secondary antibody. Filter plate loading and washing for an IgG was performed as described [Sheikholvaezin et al., 2011; Blomberg et al., 2012; Elfaitouri et al., 2013] .
Influenza A/H1N1 antibody assay. InfluenzaA/H1N1pdm2009, was used as a positive control in the RBA as the pandemic and mass vaccination coincided with the collection period 9 of the samples. InfluenzaA/H1N1pdm2009 antibodies were analyzed in 2.5 µl serum in a radioligand binding assay as described in detail [Svensson et al., 2014] .
Islet autoantibodies. Autoantibodies against glutamic acid decarboxylase, islet antigen-2, insulin and to Zn-T8 variants (Zn-T8-Arginine, Zn-T8-Tryptophan and Zn-T8-Glutamine)
were analyzed at the time of diagnosis as described [Delli et al., 2012] .
HLA genotyping. HLA-DQB1 and -DQA1 alleles were typed by sequence-specific oligonucleotide probes using a DELFIA Hybridization assay (Perkin Elmer, Boston, MA, USA) as described [Hagopian et al., 2011] .
Statistics
Statistical analyses were performed using SPSS statistical software (version 22 ® , SPSS, IBM, Chicago, Illinois, USA). Differences in proportions between groups were tested using the chi-square and two-tailed Fischer´s exact test and correlations based on absolute values by Spearman´s rho. One-way ANOVA analyses were used for comparing antibody levels between groups. p-values <0.05 were considered significant. LV antibody distribution in RBA was evaluated using Quantile-Quantile normal probability plots. A departure from a linear correlation between LV antibody levels and quantiles of a standard normal distribution would indicate a deviation from normal distribution.
Cut off for positivity was defined at the 99 th percentile of controls for the islet autoantibodies.
For LV antibodies the cut off was at the 75 th percentile of controls. Correlations were based on absolute values (Spearman) and crosstabulation on the 75 th percentile of controls.
The results in the suspension multiplex immunoassay were analyzed in the MultiPlus™ computer program, which subtracts the no-template control (NTC) and naked bead values and checks the results of control sera for each peptide and protein to store them in a relational Visual Foxpro database. The subtraction was trivial for nearly all naked bead values, which were 5-10 mean fluorescence intensity (MFI), but nontrivial for a few peptides, where the NTC values could reach 40-50. In these cases the lowest MFI obtained with some samples were often lower than the NTC value. To avoid over-subtraction, the subtraction was made with 10% of the NTC and 90% of the lowest sample value for the bead. Negative values after subtraction were set to 0 MFI. A cut off at 150 MFI was set for positive values for evaluation of significant differences in antigen reactivity.
When comparing levels of suspension multiplex immunoassay IgG with RBA LV antibody levels a cut off level was also set at 75% of controls antibody levels.
Results
IgM and IgG antibodies to LV-peptides.
Levels of LV-IgM detected in exploratory suspension multiplex assay showed inter-peptide antibody correlation (p<0.001) as did LV-IgG for all five LV-peptides (p<0.001 for all combinations, Table II 
RBA detected LV-1 antibodies
The normal probability plot indicated higher levels of LV-1 antibodies detected by the radiobinding assay at the 4 th quartile of serum samples from both controls and type 1 diabetes patients (data not shown). The RBA LV-1 antibody levels in the samples from patients (45.0; range 1-1972 U/ml) were higher than in the controls (27.0; range 3-1488 U/ml), p=0. and to Zinc transporter variants; Zn-T8-Arginine, (67%), Zn-T8-Tryptophane (57%) and Zn-T8-Glutamine (49%). LV-1 antibodies correlated to insulin autoantibody levels in the type 1 diabetes patients (r s =0.319; p=0.008) while there was no correlation to the levels of the other islet autoantibodies.
The frequency of RBA LV-1 antibodies > 75 th percentile was associated with HLA-DQ8 in patients and controls together (p=0.024, Table III ). There was an association between LV-1 antibodies and insulin autoantibodies in patients with HLA-DQ 8/8 and 8/X (p=0.014, Figure   3 ). For patients and controls together see Table IV . LV-1 antibodies were related to IgG against LV-peptide-VP1_31-60 (p=0.009, Table II ). Figure 1 ). These two peptides had 23 consecutive identical amino acids. The frequency of IgM antibodies above cut off varied 13 between 14 -27% for HPeV3-VP1_1-36, VP1_37-66, VP1_43-77 and VP1_95-124 while for the rest of the HPeV3-peptides the frequency was 1-6%.
IgM and IgG antibodies to HPeV3-peptides
IgG antibody frequency above cut off at 150 MFI was found for three of the ten HPeV3-peptides used in the analyses (Figure 2) , of which two of them had identical sequences for 23/30 amino acids (Table I) .
IgG levels were higher in type 1 diabetes patients than in controls for HPeV3-VP1_43-72, (p=0.007), HPeV3-VP1_64-93 (p<0.001), HPeV3-VP1_124-153 (p=0.04), HPeV5-VP1_31-60 (p<0.001) and HPeV2-polyprotein_1992-2021 (p=0.032).
IgG to HPeV3-VP1_1-30 (p<0.001) and to VP1_95-124 (p=0.009) but none of the other HPeV3-IgG were related to the LV-1 antibodies (Table IV) 
IgM and IgG antibodies to HPeV2, 5, 6 and 7 -peptides
The inter-peptide correlations for antibodies to HPeV2, 5, 6 and 7 were significant for both IgM (p<0.001) and IgG (p<0.001) except for both IgM and IgG against the HPeV2-polyprotein_1726-1755. The inter-IgM-IgG correlations for these peptides were significant in 22% of the combinations (data not shown).
IgM antibody frequency above the cut off at 150 MFI was found in 77-99.7% for the HPeV2-polyprotein_1992-2021, HPeV2-polyprotein_2118-2147 and HPeV5-VP1_31-60 (Figure 1 ).
IgM frequency above cut off was 20% for HPeV7_46-75, 9% for HPeV2-polyprotein_1726-1755 and 0% for HPeV5_1-30 as well as for HPeV6_51-80. IgG antibody levels above cut off at 150 MFI was found in 0 -0.6% (Figure 2 ).
14 Among the HPeV2, 5, 6, 7 peptides there was a significant correlation between LV-1 antibodies and IgG to HPeV6_51-80 (which had 52% zero values and no value above >150 MFI) in type 1 diabetes patients alone (p=0.05) as well as patients and controls combined.
Similarly, in patients and controls together, LV-1 antibodies correlated to HPeV5_31-60-IgG, which had measurable values in 16% of the samples but no value above 150 MFI.
IgM and IgG antibodies to Aichi virus and poliovirus
IgM and IgG against the one Aichi virus peptide tested correlated (p=0.02). Aichi virus above the 150 MFI cut off were found for IgM in 19% and for IgG in 0.3% of the samples.
IgM-antibodies to poliovirus peptides VP1_2150-2179 and VP1_2021-2050 above the 150 MFI cut off level were found in 100% of the samples compared to 3% for polio vaccine (Figure 1 ). The frequency of poliovirus-VP1_1769-1798 IgM-antibodies above cut off was 0.8%. IgG-antibodies to poliovirus were detected at levels above the 150 MFI cut off at a frequency of 80% for IgG to polio vaccine, 94% to poliovirus VP1_2021-2050, in 2% to VP1_2150-2179 and in 1% to VP1_1769-1798 (Figure 2 ).
Neither IgM nor IgG to Aichi virus peptide, showed any correlation to the LV-1 antibodies.
Hemophilus influenzae B vaccine antibodies
Hemophilus influenzae B IgG antibodies serving as positive control for the assay were detected in all samples and 98% of the samples had levels above the 150 MFI cut off.
RBA A/H1N1pdm2009 antibodies
The normal probability plots for A/H1N1 antibodies in controls and type 1 diabetes patients showed increased levels in the 4 th quartile. The influenzaA/H1N1 pandemic and mass vaccination period coincided with sampling time, however, only nine type 1 diabetes patients were diagnosed during this period. Over 80% of the children that left blood samples during,
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and after the pandemic and mass vaccination were vaccinated against A/H1N1pdm2009
(source: CDC, County of Jämtland, Sweden). InfluenzaA/H1N1 antibody levels showed significant increase comparing before (n=76, mean 18, range 1-125 U/ml) to during October 2009 -March 2010 (n=98, mean 95, range 2-1640 U/ml; p=0.028 compared to before), and after (n=189, mean=101, range 2-1587 U/ml; p<0.001 compared to before) the influenzaA/H1N1 pandemic and mass vaccination. There was no significant difference in levels of the other antibodies tested comparing before, during and after influenzaA/H1N1
pandemic and mass vaccination (data not shown).
Discussion
The patients and controls in the present study represent a second not previously studied cohort of type 1 diabetes patients and controls from the county of Jämtland in Sweden. In the first study patients and controls from this county were found to show an overall distribution of antibodies to LV suggesting prior exposure with varying antibody levels in the radio binding assay that primarily detect IgG [Nilsson et al., 2009] . As the first study had a limited number of patients and controls it was followed up by a study of 676 newly diagnosed type 1 diabetes patients in Region Skåne (most southern region of Sweden) ascertained over 10 years [Nilsson et al., 2013] . LV antibody levels and frequencies were comparable to the first study in Jämtland suggesting that a significant proportion of subjects, type 1 diabetes patients as well as controls, had been exposed to LV or a cross-reactive virus. Furthermore, the Skåne study suggested that LV antibodies were related to young age at onset, insulin autoantibodies and HLA-DQ8 [Nilsson et al., 2013] .
The present study is a newly ascertained cohort of Jämtland patients and controls. The major finding of this study is that LV-1 antibodies proved related to young age at onset, insulin autoantibodies and HLA-DQ8. This relationship was significant despite the present patient population was only one tenth of that of the Skåne study [Nilsson et al., 2013] . There is no sequence homology between insulin and the LV polyprotein used in the LV RBA i.e. there is no support for molecular mimicry.
The second major finding in the present study was that the IgG antibodies detected against virus peptides in the suspension multiplex immunoassay correlated between each of the different LV peptides and also to LV-1 antibodies detected by the RBA for three of them; LVIgG against VP1_31-60 and to LV-polyprotein_2193-2222 and LV-polyprotein_1799-1828.
The observation that levels of RBA detected LV-1 antibodies did not correlate to any of the 17 LV-IgM but exclusively to LV-IgG peptide antibodies would be consistent with the findings that RBA detected LV-1 antibodies primarily represents IgG1, IgG2 or IgG4 subtypes known to react with Protein A. Sepharose-protein A is used in the RBA to separate antibody-bond from free labeled antigen [Grubin et al., 1994] . The fact that the suspension immunoassay LV-peptide and LV-1 antibodies did correlate with peptides also represented in the LV cDNA used in the in vitro transcription translation is an indication that some children have been exposed to either LV or perhaps a closely related parechovirus. The time-point of exposure
was not possible to determine in the present set of samples ascertained in this cross-sectional manner. The quantile-quantile normal probability plots of binding levels may be interpreted as if the very high levels may represent more recent exposure while the lower levels may represent exposures more distant in time. The explanation would be that levels decrease over time when the antigen has been neutralized and is no longer present. This interpretation is consistent with the recent report that LV antibodies by indirect immunofluorescence showed that 38% of the Finnish population were likely to have been exposed [Jaaskelainen et al., 2013] .
It is a significant finding in the present analyses that multiplex suspension immunoassay HPeV-peptide antibodies also occurred more often in subjects positive for insulin autoantibodies and HLA-DQ8. None of the multiplex suspension immunoassay peptide antibodies, be it IgM or IgG, showed any correlation to any islet autoantibody except for the insulin autoantibodies.
It was questioned whether the RBA for LV-1 antibodies might show cross-reactivity with related viruses indicating that the antibodies detected would not be specific but rather represent HPeV antibodies that are able to immunoprecipitate the in vitro transcription translation product of the LV cDNA used in the present study. A large panel of HPeV peptides representing different parts of the viral genome was therefore prepared. The IgM and IgG analyses here did not provide strong evidence for that HPeV antibodies would solely cross-react with the LV translation product. The finding that levels of RBA LV-1 antibodies correlated with IgG to HPeV3-VP1_1-30 and -VP1_95-124 is more likely to be explained by simultaneous exposure as neither one of these two peptide IgG were related to insulin autoantibodies or HLA-DQ8. One interpretation is that it is not uncommon that subjects may have been exposed to both LV and another parechovirus. This interpretation is consistent with recent reports that a novel porcine parechovirus-like virus primarily infect young children [Yu et al., 2013] and that LV and parechoviruses are common in rodents in the UK [Salisbury et al., 2013] . Other studies suggest that parechovirus exposure in adult humans are exceedingly common [Joki-Korpela and Hyypia, 2001] and that it therefore cannot be excluded that some As the time for sample collection coincided with the epidemic and vaccination period of influenzaA/H1N1, the "new influenza" or Swine flu [Bardage et al., 2011; Svensson et al., 2014] analyses were performed for antibodies against influenzaA/H1N1 by a RBA as well.
Many, but not all, of the children in the control group were vaccinated against influenzaA/H1N1 before blood sampling. The increasing frequency of antibodies to influenzaA/H1N1 in the samples collected from autumn of 2009 onwards would be consistent with the pandemic and mass vaccination period.
In conclusion, the present study in type 1 diabetes patients and controls ascertained in Jämtland county in Northern Sweden suggests that these individuals have been exposed to LV, measured as both IgG antibodies against LV-1 and suspension multiplex immunoassay.
Possible antibody cross-reactivity of LV and HPeV cannot be excluded. However, the study supports previous observations that LV but not HPeV antibodies were related to type 1 diabetes as LV antibody titers were related to insulin autoantibodies, but not to other autoantibodies. Most stringent associations were found in young age-at-onset type 1 diabetes children and positive for HLA-DQ8. IgM and IgG antibodies against poliovirus, influenza or Haemophilus B did not show any relationship to type 1 diabetes or HLA-DQ. These data further support the notion that exposure to LV, or a closely related virus at a young age, may be related to the risk of type 1 diabetes. Peptide abbreviations are shown in Table I . Antibody levels are shown on a logarithmic scale. X=neither 2 nor 8.
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